Exelixis Company Profile

Aggregated data from the web about Exelixis

Company Name	Exelixis
Website	https://www.exelixis.com
Snippet	Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer. Read More. 02/28/2023. Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March. Read More.
Type	Public
Founded	1994
Revenue	US$ 1.0 Billion (2019)[2]
Website	exelixis.com
Formerly	Exelixis Pharmaceuticals, Inc.(1994-2000)
Industry	Biotechnology
Traded as	NASDAQ: EXEL, S&P 400 component
Key people	Stelios Papadopoulos, Ph.D.(Chairman)Michael M. Morrissey, Ph.D.(President & CEO)[1]
Net income	US$ 154.23 million (2017)
Headquarters	Alameda, California, U.S.
Total assets	US$ 655.29 million (2017)
Total equity	US$ 284.96 million (2017)
Operating income	US$ 165.91 million (2017)
Number of employees	ca. 484 (12/2019)[1]

Exelixis is part of the United States company list

Exelixis is part of the Biotechnology company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.